Department of Biological Sciences and Environmental Sciences Program, Southern Illinois University-Edwardsville, Edwardsville, IL, 62026, USA.
Department of Integrated Biomedical and Life Science, Graduate School, Korea University, Seoul, 02841, Republic of Korea.
BMC Complement Altern Med. 2019 Jul 31;19(1):195. doi: 10.1186/s12906-019-2610-9.
Probiotics have been reported to be the active component used in the treatment of many functional gastrointestinal symptoms and syndromes. Lactobacillus and yeast culture are extensively used in probiotic supplements and traditional treatments for irritable bowel syndrome (IBS). The aim of this study was to investigate the effects of probiotic treatments (Lactobacillus acidophilus LA5, Bifidobacterium animalis subsp. lactis BB12 and Saccharomyces cerevisiae var. boulardii) on the behavioral response, targeted gene expression and pro-inflammatory cytokine levels of Pi (Post infectious)-IBS -induced mice.
Pathogen-free male C57L/B6 mice and the Trichinella-infected mice were used to measure the score of abdominal withdrawal reflex (AWR). To compare molecular, biological and biochemical evidences of given probiotics with normal and positive control groups in mice, we conducted quantitative reverse transcription polymerase chain reaction (RT-qPCR), western blotting, and cytokine analysis.
Pi-IBS-induced immune response was confirmed that PAR-2 mRNA level was significantly increased by Trichinella infection (P < 0.05). The reduction of Pi-IBS symptoms through Trichinella infection and the effects of given probiotics were confirmed by a change in the protein levels of cytokines (P < 0.05). In addition, the administration of DW (Daewon) probiotics significantly decreased serum levels of IL-1 and IL-6 (P < 0.05).
We have demonstrated that the given probiotics decreased pro-inflammatory cytokine levels in both the control and Pi-IBS induced mice. Taken all the results together, the results support that DW probiotics has a potential as a probiotic medication for patient with IBS via regulating TNF-α and IL-6 protein levels and serum IL-1 and IL-6 levels.
益生菌已被报道是治疗多种功能性胃肠症状和综合征的有效成分。乳杆菌和酵母培养物广泛用于益生菌补充剂和肠易激综合征(IBS)的传统治疗。本研究旨在研究益生菌治疗(嗜酸乳杆菌 LA5、动物双歧杆菌亚种乳双歧杆菌 BB12 和酿酒酵母 var. 布拉迪)对感染后肠易激综合征(PI-IBS)诱导的小鼠行为反应、靶向基因表达和促炎细胞因子水平的影响。
使用无病原体雄性 C57L/B6 小鼠和旋毛虫感染小鼠来测量腹部退缩反射(AWR)评分。为了比较正常和阳性对照组中小鼠中给予的益生菌的分子、生物学和生物化学证据,我们进行了定量逆转录聚合酶链反应(RT-qPCR)、蛋白质印迹和细胞因子分析。
PI-IBS 诱导的免疫反应证实,旋毛虫感染可使 PAR-2 mRNA 水平显著升高(P<0.05)。通过旋毛虫感染和给予益生菌来减轻 PI-IBS 症状得到了证实,这表现在细胞因子的蛋白水平发生了变化(P<0.05)。此外,DW(大元)益生菌的给药显著降低了血清中 IL-1 和 IL-6 的水平(P<0.05)。
我们已经证明,给予的益生菌降低了对照和 PI-IBS 诱导的小鼠中的促炎细胞因子水平。综合所有结果,这些结果支持 DW 益生菌通过调节 TNF-α 和 IL-6 蛋白水平以及血清 IL-1 和 IL-6 水平,具有作为 IBS 益生菌药物的潜力。